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Impact of High Volume Energy Drink Consumption on
Electrocardiographic and Blood Pressure Parameters: A Randomized
Trial
Sachin A. Shah, PharmD; Andy H. Szeto, PharmD; Raechel Farewell, PharmD; Allen Shek, PharmD; Dorothy Fan, PharmD; Kathy N. Quach,
PharmD; Mouchumi Bhattacharyya, PhD; Jasmine Elmiari, BA; Winny Chan; Kate O’Dell, PharmD; Nancy Nguyen, PharmD;
Tracey J. McGaughey, PharmD; Javed M. Nasir, MD; Sanjay Kaul, MD
Background-—Energy drinks have been linked to an increase in emergency room visits and deaths. We aim to determine the
impact of energy drinks on electrocardiographic and hemodynamic parameters in young healthy volunteers.
Methods and Results-—A randomized, double-masked, placebo-controlled, crossover study was conducted in healthy volunteers.
Participants consumed 32 oz of either energy drink A, energy drink B, or placebo within 60 minutes on 3 study days with a 6-day
washout period in between. The primary end point of QTc interval and secondary end points of QT interval, PR interval, QRS
duration, heart rate, and brachial and central blood pressures were measured at baseline, and every 30 minutes for 240 minutes.
A repeated-measures 2-way analysis of variance was performed with the main effects of intervention, time, and an interaction of
intervention and time. Thirty-four participants were included (age 22.13.0 years). The interaction term of intervention and time
was statistically significant for Bazett’s corrected QT interval, Fridericia’s corrected QT interval, QT, PR, QRS duration, heart rate,
systolic blood pressure, diastolic blood pressure, central systolic blood pressure, and central diastolic blood pressure (all P<0.001).
The maximum change from baseline in Bazett’s corrected QT interval for drinks A, B, and placebo were +17.913.9, +19.615.8,
and +11.911.1 ms, respectively (P=0.005 for ANOVA) (P=0.04 and <0.01, respectively compared with placebo). Peripheral and
central systolic and diastolic blood pressure were statistically significantly different compared with placebo (all P<0.001).
Conclusion-—Energy drinks significantly prolong the QTc interval and raise blood pressure.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03196908. ( J Am Heart Assoc. 2019;8:
e011318. DOI: 10.1161/JAHA.118.011318.)
Key Words: blood pressure • electrocardiography • energy drinks • hemodynamics • QT interval electocardiography
E nergy drinks are a growing industry with a market valuepredicted to reach $61 billion by 2021.1 It is estimated
that about 30% of teenagers between the ages of 12 through
17 years in the United States consume energy drinks on a
regular basis.2 A study of military personnel found that nearly
45% of deployed service members consumed at least 1 energy
drink per day with 14% drinking ≥3 daily.3 Although commonly
promoted as supplements that can boost performance and
cognition, these drinks have also been reported to have
numerous detrimental side effects, particularly cardiovascular
and neurological in nature.4–6 The number of annual emer-
gency department visits involving energy drinks increased
from 10 068 in 2007 to 20 783 in 2011.7 According to the
Food and Drug Administration, there have been 34 deaths
attributed to energy drinks warranting investigation into the
safety of these beverages.8
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Energy drink consumption has been associated with
cardiac arrest, myocardial infarction, spontaneous coronary
dissection, and coronary vasospasm.9–16 This association is
strengthened with studies showing increased platelet aggre-
gation, increased systolic blood pressure (SBP), and QTc
prolongation.17–20 QT/QTc interval prolongation is a biolog-
ically plausible reason for the sudden cardiac arrest associ-
ated with energy drinks and QTc prolongation places patients
at increased risk for developing torsades de pointes, which
can lead to fatal ventricular arrhythmias.21 Several small
studies have demonstrated mild QTc prolongation with energy
drink consumption but the data remain controversial because
of energy drink dose and study design-related con-
founders.19,20,22,23 To validate previous electrocardiographic
findings and to assess the differences between energy drink
types, we conducted a randomized, double-masked, placebo-
controlled, crossover study in young healthy volunteers.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
This study was approved by the Institutional Review Board
(IRB) at University of the Pacific (Stockton, CA). All partici-
pants were provided written informed consent consistent with
university requirements for clinical studies involving human
subjects. The clinical study was registered on ClinicalTria
ls.gov (NCT03196908).
This was a randomized, double-masked (participants and
care providers), placebo-controlled, crossover clinical trial
conducted at a university campus setting (July 2017 to
December 2017). Healthy volunteers between the ages of 18
and 40 years who were willing to avoid ingestion of caffeine
and energy drinks for 48 hours before each study day were
eligible for enrollment. Participants were excluded if they had
any known medical condition (confirmed through participant
interview), were pregnant or breastfeeding, were current
smokers, had a baseline QTc >450 ms, or brachial blood
pressure >140/90 mm Hg. Those who were taking any
chronic prescription or over-the-counter medications were
excluded except those who had been taking oral contracep-
tives for over 1 month. An overnight fast (with allowance for
water only) was required preceding every study day, and no
food was allowed during the study monitoring period. A
commercially available non-caffeinated granola bar (Nature
Valley Crunchy Oats ‘N Honey, General Mills) was provided
after the 180-minute time point upon participant request.
Participants were randomized into 1 of 3 intervention
phases using a computer-generated code from http://www.
randomization.com. Participants received two 16-oz bottles of
a commercially available caffeinated energy drink brand (drink
A), another brand of a caffeinated energy drink (drink B), or a
placebo-drink (placebo) on 3 separate days with a minimum
6-day washout period in-between. The beverages were
consumed within a 60-minute period but no faster than 1
bottle in 30 minutes. Based on the package labeling, both
drink A and drink B contained caffeine (304–320 mg/32-fl
oz), taurine, glucuronolactone, and vitamins along with other
proprietary ingredients.24 Some differences between the 2
energy drink brands include the presence of carnitine,
guarana, and panax ginseng. The placebo drink contained
carbonated water, lime juice, and cherry flavoring. All drinks
were packaged in identical, masked containers prepared
within 24 hours of administration and stored in a refrigerator
before administration.
End Point Measurement
The primary end point was QTc interval. Secondary end points
included the QT interval (QT), PR interval (PR), QRS duration
(QRSd), heart rate (HR), systolic blood pressure (SBP),
diastolic blood pressure (DBP), central systolic blood pressure
(cSBP), and central diastolic blood pressure (cDBP). Augmen-
tation index (AI) adjusted to an HR of 75 bpm was also
measured and will be reported in a separate analysis. All end
points were measured at baseline and at 30, 60, 90, 120,
150, 180, 210, and 240 minutes on each study day.
Participants began the study at approximately the same time
each study day to account for circadian rhythm changes.
A standard 12-lead ECG (PageWriter Trim III or TC20,
Phillips) was obtained with participants in the supine position.
ECGs were performed in triplicate at each time point
1 minute apart and averaged. The machine reported HR,
PR interval, QRSd, QT interval, and QTc interval (Bazett’s
formula [QTcB]) end points were used for analysis. QTc was
also corrected using Fridericia’s formula (QTcF) where
QTcF=QT/cube-root of (RR interval).
Blood pressure measurements were obtained in the seated
position after an initial rest period of 8 minutes using an
automated blood pressure device (SphygmoCor XCEL PWA,
AtCor Medical). SphygmoCor provides automated brachial
Clinical Perspective
What Is New?
• The class of energy drinks, rather than one particular
product affect the QTc interval and blood pressure.
What Are the Clinical Implications?
• Individuals with acquired or congenital long QT syndrome
and those with hypertension should be more vigilant and
limit their energy drink intake.
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blood pressure as well as non-invasive analysis of the central
aortic blood pressure waveform and related hemodynamic
parameters. Two measurements were taken at each time
point 2 minutes apart on the right arm and averaged.
Statistical Analysis
Based on previous studies, assuming a difference of 6 ms in
the QTc interval in the baseline-adjusted, placebo-corrected
changes between the 2 energy drinks (SD=11 ms, 80%
power, and a=5%), 29 volunteers would be needed for the
study.25 We planned to enroll 40 participants anticipating
25% dropout rate. An intention-to-treat analysis was
performed using the last-observation-carried-forward method-
ology to account for missing data.
A repeated-measures analysis of variance, which assumes
a compound symmetry covariance structure, was performed
with the main effects of intervention, time, and an interaction
of intervention and time (R version 3.5.2). The authors verified
that this assumption was a reasonable one for their data.
Results of this analyses called for a 2-way analysis of variance
for each end point (baseline-adjusted) at each time point, with
a post hoc Tukey Honestly Significant Difference (HSD), to
assess for differences between the 3 interventions (adjusted
for subject variability, however, not adjusted for multiple time
points) (Table S1). In addition, the maximum value for each
end point within each time frame (30–240 minutes) was
identified (referred to as the “maximum” time point) to assess
the peak effect because of interindividual variability and was
analyzed in the same manner as above. The data were also
analyzed using the Bonferroni adjustment, which did not
change the interpretation of the study (data not included).
Finally, the baseline-adjusted, placebo-corrected changes
between drink A and drink B were also compared using the
paired t test. Data analyses were independently performed by
a masked statistician. All QTc data are reported using the
Bazett’s correction formula unless explicitly stated otherwise.
Data are reported as meanSD except in figures (meanSE).
Results
Forty-four participants were screened, 40 were randomized,
and 34 ultimately included for analysis. Baseline demograph-
ics are listed in Table 1. None of the participants were on any
medications other than 3 who were on oral contraceptives.
Two participants requested a granola bar after 180 minutes
and 5 requested a granola bar after 210 minutes (1 requested
a bar on 2 of the study days after 210 minutes). On the days
of such requests, 3 participants had received drink A, 4 had
received drink B, and 1 had received placebo. Data imputation
for missing data was performed for <0.7% of the data. Table 2
describes ECG and blood pressure parameters at baseline.
The interaction term of intervention and time was statis-
tically significant for QTcB, QTcF, QT, PR, QRSd, HR, SBP, DBP,
cSBP, and cDBP (all P<0.001). When assessing the interven-
tion effect alone, a statistically significant difference was
noted in cSBP, cDBP, SBP, and DBP (all P<0.001) while a
trend towards significance was observed for QTcB and QTcF
(P=0.082 and 0.064 for ANOVA, respectively). There was no
statistically-significant difference between interventions in PR,
QRSd, QT, and HR. These statistically significant findings
warranted further analyses of the interventions at individual
time points (Table S1).
Table 3 describes the maximum change from baseline in
each intervention across all end points. The maximum change
from baseline in QTcB for drink A, drink B, and placebo were
+17.913.9, +19.615.8, and +11.911.1 ms, respectively
(P=0.005 for ANOVA). The maximum QTcB changes with drink
A and drink B were each statistically significantly different
from placebo (P=0.037 and 0.006, respectively). The change
from baseline in QTcB with drink A and drink B was
statistically significantly greater than placebo at 180, 210,
and 240 minutes (all P≤0.025) (Figure 1). Two participants
(baseline QTcB 401 and 425 ms) had a change from baseline
in QTcB interval over 50 ms with drink A and drink B. In
Table 1. Patient Characteristics
Characteristic Total






18 to 24 20 (58.8)











BMI indicates body mass index.
*Rare caffeine consumers were defined as <1 caffeine containing drink per month,
occasional caffeine consumers were defined as 1 to 3 drinks per month, frequent
caffeine consumers were defined as 1 to 6 caffeine containing drinks per week, daily
caffeine consumers were defined as ≥1 caffeine containing drink per day.
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contrast, none of the participants receiving placebo had a
change from baseline in QTcB interval over 50 ms. None of
the participants had a QTcB or QTcF >500 ms at any point.
The maximum changes from baseline in SBP for drink A,
drink B, and placebo were +15.95.0, +14.44.8, and
+9.84.8 mm Hg, respectively (P<0.001 for ANOVA)
(Table 3). The maximum SBP changes with drink A and drink
B were statistically significantly higher from placebo (P<0.001
for both) (Table 3). The change from baseline in SBP with
drink A and drink B was statistically significantly higher at all
time points (all P≤0.027) (Figure 2) when compared with
placebo. Post-dosing SBP was ≥140 mm Hg (and
≤160 mm Hg) in 9, 8, and 2 participants for drink A, drink
B, and placebo, respectively.
The maximum change from baseline in QT, DBP, cSBP,
cDBP for drink A, drink B, and placebo were also significantly
different (all P≤0.026 for ANOVA) (Table 3). The maximum
change from baseline for the PR interval, QRSd, and HR, were
not significantly different (all P≥0.076 for ANOVA) (Table 3).
The maximum baseline-corrected, placebo-adjusted change
in QTcB with drink A was +6.115.0 ms compared with
+7.716.4 ms with drink B (P=0.337). The maximum baseline-
corrected, placebo-adjusted change in SBP with drink A was
+6.15.5 mm Hg compared with +4.65.0 mm Hg with drink
B (P=0.151). Similarly, the maximum baseline-corrected,
placebo-adjusted changes for all other ECG and hemodynamic
end points were not different when comparing drink A and drink
B (all P≥0.151). The supplement table lists the average change
frombaseline for each endpoint across thedifferent timepoints.
Discussion
To our knowledge, this is the largest, controlled study,
indicating acute-consumption of 32 oz of a caffeinated energy
drink significantly prolongs the QTc interval when compared
with placebo. According to the Food and Drug Administration,
QTc prolongation is a well-established risk factor for arrhyth-
mias, with a prolongation over 10 ms prompting further
investigation.26,27 Clinically, a QT/QTc interval >500 ms or a
change >30 ms warrants careful monitoring.28 Drugs such as
ranolazine and terfenadine carry warnings, or have been
removed from the market because of prolongation of the
mean QT/QTc by 6 ms.29,30
Three smaller studies have evaluated the impact of
consuming 32 oz of energy drinks on heart rhythm vari-
ables.19,25,31 In a non-controlled study (n=14) by Kozik et al,
57% of the healthy participants had a QTc >500 ms after
consuming 32 oz of the energy drink.31 In a small (n=18)
randomized, caffeine-controlled clinical trial, 32 oz of an
energy drink resulted in a significantly higher QTc at 2 hours
when compared with the caffeinated control (+0.418.4 ms
versus 10.414.8 ms, respectively; P=0.02).19 In another
similar placebo-controlled trial (n=27), the QTc interval was
transiently higher (6 ms) at 2 hours after 32-oz energy drink
consumption when compared with placebo (+3.410.7 and
3.211.8 ms, respectively; P=0.030).25 The results of our
study confirm these previous findings and suggest that the
QTc changes are generally sustained over the 4 hour
Table 2. Baseline Cardiovascular Parameters (n=34)
Cardiovascular
Parameters Drink A Drink B Placebo
HR, bpm 63.5 (8.2) 63.2 (10.0) 62.5 (7.2)
PR, ms 158.0 (17.1) 157.9 (20.2) 156.4 (18.3)
QRSd, ms 92.3 (13.3) 93.1 (14.1) 93.0 (14.2)
QT, ms 403.4 (20.8) 404.5 (20.5) 407.1 (20.3)
QTcB, ms 412.9 (20.9) 412.3 (22.9) 413.7 (18.7)
QTcF, ms 409.8 (16.8) 409.7 (16.1) 411.6 (15.4)
SBP, mm Hg 116.9 (10.0) 118.5 (9.6) 118.2 (9.0)
DBP, mm Hg 73.4 (7.8) 74.2 (8.4) 73.9 (7.9)
cSBP, mm Hg 104.0 (9.4) 105.3 (8.8) 104.8 (7.9)
cDBP, mm Hg 74.4 (8.0) 75.2 (8.4) 74.8 (8.0)
All data reported as mean (SD). cDBP indicates central diastolic blood pressure; cSBP,
central systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PR, PR
interval; QRSd, QRS duration; QT, QT interval; QTcB, Bazett’s corrected QT interval; QTcF,
Fridericia’s corrected QT interval; SBP, systolic blood pressure.
Table 3. Average Maximum Change in Cardiovascular
Parameters (n=34)
Drink A Drink B Placebo P Value*
ECG parameters†
QTcB, ms 17.9 (13.9)‡ 19.6 (15.8)§ 11.9 (11.1) 0.005
QTcF, ms 15.0 (11.8)‡ 15.2 (11.9)§ 6.9 (7.1) <0.001
QT, ms 18.4 (17.0)‡ 15.8 (13.3) 10.2 (12.2) 0.026
PR, ms 5.4 (6.5) 6.1 (7.5) 8.6 (6.6) 0.076
QRSd, ms 6.2 (3.3) 5.9 (3.0) 5.0 (2.9) 0.164
HR, bpm 7.7 (7.4) 7.2 (6.8) 7.4 (5.9) 0.918
Hemodynamics†
SBP, mm Hg 15.9 (5.0)‡ 14.4 (4.8)§ 9.8 (4.8) <0.001
DBP, mm Hg 9.6 (4.1)‡ 9.6 (4.9)§ 6.1 (3.8) <0.001
cSBP, mm Hg 11.1 (4.7)‡ 10.1 (4.8)§ 6.5 (3.5) <0.001
cDBP, mm Hg 9.9 (4.2)‡ 9.8 (5.1)§ 6.7 (3.5) <0.001
All data reported as mean (SD). cDBP indicates central diastolic blood pressure; cSBP,
central systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PR, PR
interval; QRSd, QRS duration; QT, QT interval; QTcB, Bazett’s corrected QT interval; QTcF,
Fridericia’s corrected QT interval; SBP, systolic blood pressure.
*P value for analysis of variance adjusted for subject variability.
†No statistically significant difference was noted between drink A and drink B for any
parameter.
‡Statistically significant difference between drink A and placebo.
§Statistically significant difference between drink B and placebo.
DOI: 10.1161/JAHA.118.011318 Journal of the American Heart Association 4
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monitoring period versus being a transient effect after 32-oz
energy drink consumption.
The results are inconsistent in other studies where energy
drink volumes under 32 oz were investigated. Brothers et al
(n=15) reported no changes in the QTc over 6.5 hours post-
consumption of a 24-oz energy drink.22 Tauseef et al found QTc
prolongation of 13 ms after 500 mL (16.9 ounce) energy drink
consumption.20 An Australian study enrolled patients with
congenital long QT-syndrome (n=24) and found no statistically
significant changes within 90 minutes after consumption of
500 mL (16.9 ounce) of an energy drink. However, 3 patients
did have a QTc increase >50 ms when compared with
baseline.23 One parallel designed study assessed the impact
of consuming 460 mL of 3 different types of caffeinated energy
drinks on ECG parameters with no clinically significant
changes.32
In this study, both energy drinks had a similar effect on
electrocardiographic parameters. Common ingredients con-
tained in this study’s products included a combination of
caffeine, taurine, glucuronolactone, and B-vitamins. Caffeine
at doses under 400 mg is not expected to induce any
electrocardiographic changes.33 Taurine is an endogenous
molecule and supplementation is believed to be anti-
arrhythmic rather than pro-arrhythmic.34,35 In animal models
evaluating short QT syndrome, a taurine-magnesium coordi-
nation compound has been shown to prolong the QT interval
in a dose-dependent manner.36 Data on glucuronolactone and
B-vitamins are limited but they are typically regarded as
safe.37 Although the preponderance of data suggest these
ingredients may be safe individually, their use in combination
requires evaluation.
There was an 5 and 4 mm Hg increase in SBP and DBP,
respectively after energy drink consumption relative to
placebo. A previous meta-analysis of 15 studies including
>300 participants similarly suggested a 4- and 3-mm Hg
change in SBP and DBP independent of dose.18 An emerging
predictor of cardiovascular risk is cSBP.38 In this study, cSBP
was significantly elevated after energy drink consumption but
the long-term consequences remain unknown.
While blood pressure changes can be attributed primarily to
the caffeine, other ingredients in energy drinks may pose some
hemodynamic activity.37 Taurine has been shown to lower
blood pressure in prehypertensive patients, indicating the need





















Drink A Drink B Placebo
Figure 1. Change in QTcB from baseline over time. QTcB indicates Bazett’s corrected QT interval.
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Caffeine and ephedra-containing supplements were with-
drawn from market after discovery of adverse QTc interval
effects.40 Additionally, a sustained elevation in SBP of
2 mm Hg is associated with a 7% increased risk of mortality
from ischemic heart disease and a 10% increased risk of
stroke mortality.41 The cardiovascular effects seen in this
study warrant concern as the observation of increased
cardiovascular adverse effects and fatalities related to energy
drinks remains an important public health issue.42
Several factors may limit the generalizability of this study.
We did not investigate the effects of different doses and the
volume of drink consumed (two 16-ounce cans over 60 min-
utes) in this study may not be representative of real-world
consumption patterns. However, 24-oz variants of certain
energy drink brands are readily available, facilitating consump-
tion of larger volumes of energy drink in one sitting. In a survey
of 2040 respondents, 16% reported having once consumed >2
energy drinks in a day.43 We assessed the effects of acute
consumption of an energy drink <4 hours, which does not lend
insight to long-term effects nor the effects of chronic
consumption. Additionally, we assessed energy drink con-
sumption alone, and it is not uncommon for energy drinks to be
consumed in combination with other substances such as
alcohol.44,45 While all products were packaged identically, it is
possible that some participants were able to identify the energy
drink or placebo drinks based on taste or pharmacodynamic
response. Our study included only healthy individuals between
the ages of 18 to 40 years and results may not be applicable to
populations with concomitant comorbidities or those who are
not within the studied age range. We did not independently test
the concentrations of the ingredients in the energy drinks but
relied on publicly available data.
Significant prolongation in the QT interval was also evident
within the first hour after energydrink consumption but these are
thought to be HR related changes. There appears to be a mild PR
shortening effect and is currently thought to be clinically non-
significant. Most previous studies used the Bazett’s correction
formula, but it is known to under correct at low heart rates.46
Conversely, the Fridericia formula has been shown to be an
acceptable alternate correction formulawhen comparedwith the
Bazett’s.47 Our results are significant regardless of the heart rate
correction formula used (Bazett’s or Fridericia’s). However, it is
important to note that QTc prolongation does not necessitate
onset of torsades de pointes and is simply a risk factor. While our
study incorporatesmanyaspects of a “ThoroughQT/QTcStudy”,
assay-sensitivity could not be assessed due to the lack of a
positive-control (eg, moxifloxacin).27
Individuals with acquired or congenital long QT syndrome
and those with hypertension should be more vigilant and limit


















Drink A Drink B Placebo
Figure 2. Change in SBP from baseline over time. SBP indicates systolic blood pressure.
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the class of energy drinks, rather than one particular product,
warrants use with caution.
Conclusions
Caffeinated energy drinks significantly prolong the QTc
interval and raise brachial and central blood pressure post-
acute exposure. Further investigation is warranted on whether
an individual ingredient or a unique combination leads to the
observed electrophysiological and hemodynamic changes.
The impact of long-term energy drinks consumption remains
unknown.
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Table S1.  Average Change in All Parameters at Each Time Point  
Parameter§ Drink A Drink B Placebo P value* 
QTcB, ms      
30 mins 0.1 (9.1) -0.1 (10.7) -0.1 (8.5) 0.99 
60 mins 8.4 (15.0) 8.8 (14.5) 7.9 (11.8) 0.93 
90 mins 9.0 (13.3) 6.3 (16.0) 5.4 (12.7) 0.32 
120 mins 3.5 (13.7) 6.4 (14.7) 3.0 (11.4) 0.33 
150 mins 1.0 (12.6) 2.7 (13.2) -2.4 (12.8) 0.06 
180 mins 2.7 (14.9)† 4.7 (18.0)‡ -4.5 (12.3) <0.01 
210 mins 7.2 (16.1)† 8.2 (14.8)‡ -2.4 (10.1) <0.001 
240 mins 10.2 (13.8)† 8.3 (15.1)‡ -1.1 (12.9) <0.001 
Max 17.9 (13.9)† 19.6 (15.8)‡ 11.9 (11.1) <0.01 
QTcF, ms      
30 mins 1.0 (5.8) 1.4 (8.1) -0.6 (5.7) 0.32 
60 mins 5.4 (9.2) 6.2 (9.7) 2.5 (7.7) 0.07 
90 mins 3.8 (8.1) 3.0 (9.6) -0.1 (9.2) 0.05 
120 mins -0.6 (8.7) 1.9 (8.6) -1.5 (8.6) 0.10 
150 mins -1.5 (8.5) -0.6 (8.5) -4.0 (9.0) 0.11 
180 mins 2.0 (10.2)† 3.6 (14.0)‡ -3.8 (9.1) <0.01 
210 mins 7.8 (13.9)† 8.2 (10.9)‡ -0.7 (7.7) <0.001 
240 mins 12.3 (12.5)† 9.7 (12.0)‡ 1.0 (9.5) <0.001 
Max 15.0 (11.8)† 15.2 (11.9)‡ 6.9 (7.1) <0.001 
QT, ms  
    
30 mins 2.8 (9.3) 4.2 (10.7)‡ -1.4 (11.3) 0.03 
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90 mins -5.9 (14.3) -3.7 (10.1) -10.5 (12.7) 0.07 
120 mins -8.6 (14.0) -7.0 (12.6) -10.5 (12.9) 0.58 
150 mins -6.4 (12.8) -7.3 (11.9) -7.1 (12.6) 0.96 
180 mins 0.3 (13.6) 1.0 (15.9) -2.4 (13.8) 0.55 
210 mins 8.9 (19.6) 8.0 (13.9) 2.5 (14.3) 0.15 
240 mins 16.1 (18.3)† 12.0 (14.0) 5.3 (11.5) <0.01 
Max 18.4 (17.0)† 15.8 (13.3) 10.2 (12.2) 0.03 
PR, ms  
    
30 mins 1.7 (6.4)† 2.2 (6.0) 5.1 (6.2) 0.03 
60 mins 1.4 (8.8) 3.5 (8.3) 4.9 (8.0) 0.10 
90 mins -2.2 (8.6)† -0.7 (7.6) 3.5 (7.3) <0.01 
120 mins -2.3 (9.0) -2.0 (8.7) 0.2 (7.2) 0.33 
150 mins -4.9 (9.8) -3.0 (7.2) -1.2 (6.1) 0.10 
180 mins -5.0 (9.3) -5.2 (6.1) -2.7 (6.0) 0.24 
210 mins -8.7 (9.7)† -7.9 (7.4)‡ -2.7 (6.7) <0.01 
240 mins -7.0 (8.5) -7.7 (7.1)‡ -3.4 (6.9) 0.04 
Max 5.4 (6.5) 6.1 (7.5) 8.6 (6.6) 0.08 
QRSd, ms  
    
30 mins 3.8 (3.5) 3.0 (2.7) 3.1 (3.0) 0.37 
60 mins 5.0 (3.5) 4.5 (3.8) 3.9 (3.2) 0.35 
90 mins 4.0 (3.8) 3.0 (3.4) 2.8 (3.0) 0.16 
120 mins 2.3 (3.0) 1.3 (3.6) 1.5 (3.5) 0.28 
150 mins 0.9 (4.0) 1.0 (3.5) 0.3 (3.9) 0.64 
180 mins 1.9 (3.8)† 0.6 (3.0) -0.5 (3.4) 0.01 
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240 mins 2.6 (3.8)† 1.7 (2.8)‡ -0.3 (2.9) <0.01 
Max 6.2 (3.3) 5.9 (3.0) 5.0 (2.9) 0.16 
HR, bpm  
    
30 mins -0.8 (4.2) -1.4 (4.6) 0.6 (4.9) 0.10 
60 mins 3.0 (7.9) 2.3 (6.4) 5.2 (6.2) 0.07 
90 mins 5.2 (8.4) 3.0 (7.1) 5.2 (6.3) 0.23 
120 mins 4.0 (7.9) 4.0 (7.6) 4.3 (5.7) 0.95 
150 mins 2.4 (6.9) 2.9 (6.4) 1.6 (5.8) 0.63 
180 mins 0.6 (7.2) 0.8 (6.7) -0.5 (5.6) 0.62 
210 mins -0.6 (7.4) 0.1 (6.8) -1.3 (5.3) 0.60 
240 mins -1.9 (6.5) -1.4 (5.5) -1.8 (5.2) 0.92 
Max 7.7 (7.4) 7.2 (6.8) 7.4 (5.9) 0.92 
SBP, mmHg 
    
30 mins 9.5 (5.0)† 8.0 (4.6)‡ 5.0 (5.0) <0.01 
60 mins 13.5 (5.5)† 11.5 (5.5)‡ 7.3 (6.2) <0.001 
90 mins 11.1 (6.7)† 9.7 (6.5)‡ 4.7 (5.4) <0.001 
120 mins 10.7 (5.5)† 8.0 (6.0)‡ 3.5 (5.0) <0.001 
150 mins 7.2 (4.0)† 7.7 (5.5)‡ 1.5 (4.8) <0.001 
180 mins 6.8 (5.5)† 7.5 (5.1)‡ 1.5 (5.5) <0.001 
210 mins 6.8 (5.1)† 5.9 (5.2)‡ 2.5 (5.1) <0.001 
240 mins 9.0 (4.6)† 7.8 (5.4)‡ 4.2 (4.5) <0.001 
Max 15.9 (5.0)† 14.4 (4.8)‡ 9.8 (4.8) <0.001 
DBP, mmHg  
    
30 mins 4.5 (4.7)† 4.5 (4.4)‡ 1.7 (4.2) 0.01 
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90 mins 6.4 (4.6)† 5.5 (4.6)‡ 2.2 (4.2) <0.001 
120 mins 5.8 (4.3)† 5.2 (3.9)‡ 1.2 (3.1) <0.001 
150 mins 5.5 (4.5)† 6.1 (5.1)‡ 1.1 (4.0) <0.001 
180 mins 4.6 (5.9)† 4.3 (6.1)‡ 0.8 (3.8) <0.001 
210 mins 1.4 (5.1) 2.7 (5.2) 1.1 (3.9) 0.28 
240 mins 3.0 (4.6) 3.3 (5.3) 2.4 (4.6) 0.69 
Max 9.6 (4.1)† 9.6 (4.9)‡ 6.1 (3.8) <0.001 
cSBP, mmHg  
    
30 mins 6.6 (5.2)† 5.7 (4.9)‡ 2.8 (4.2) <0.01 
60 mins 8.9 (5.2)† 7.4 (5.6)‡ 3.2 (4.6) <0.001 
90 mins 6.8 (5.9)† 5.5 (5.5)‡ 1.7 (5.2) <0.001 
120 mins 6.4 (5.1)† 4.6 (5.3)‡ 0.7 (3.9) <0.001 
150 mins 4.6 (3.8)† 4.7 (5.3)‡ -0.5 (4.5) <0.001 
180 mins 4.0 (4.8)† 4.6 (5.3)‡ -0.6 (4.7) <0.001 
210 mins 2.9 (4.5) 3.3 (5.2)‡ 0.6 (4.8) 0.02 
240 mins 4.9 (4.6)† 4.1 (5.0) 1.9 (4.7) 0.02 
Max 11.1 (4.7)† 10.1 (4.8)‡ 6.5 (3.5) <0.001 
cDBP, mmHg  
    
30 mins 4.6 (4.6)† 4.5 (4.7) 2.1 (4.2) 0.03 
60 mins 7.6 (4.3)† 6.9 (5.3)‡ 3.4 (3.8) <0.001 
90 mins 7.0 (5.1)† 6.0 (4.9)‡ 2.9 (4.2) <0.001 
120 mins 6.3 (4.6)† 5.8 (4.1)‡ 2.0 (3.2) <0.001 
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All data reported as mean (standard deviation). cDBP, central diastolic blood pressure; DBP, diastolic blood 
pressure; cSBP, central systolic blood pressure; HR, heart rate; PR, PR interval; QRSd, QRS duration; QT, QT 
interval; QTcB indicates Bazett’s corrected QT interval; QTcF, Fridericia’s corrected QT interval; SBP, systolic 
blood pressure.  
*P<0.05 for analysis of variance adjusted for subject variability 
†Statistically significant difference between Drink A and Placebo 
‡Statistically significant difference between Drink B and Placebo 
§No statistically significant difference was noted between Drink A and Drink B for any parameter 
180 mins 4.6 (6.0)† 4.1 (6.4)‡ 1.2 (3.7) <0.01 
210 mins 1.5 (5.2) 2.7 (5.2) 1.3 (4.0) 0.34 
240 mins 3.0 (4.5) 3.3 (5.3) 2.6 (4.5) 0.81 
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